Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics

J. Nicholls, Stephen; L. Bhatt, Deepak; B. Buse, John; Del Prato, Stefano; E. Kahn, Steven; Michael Lincoff, A.; K. McGuire, Darren; A. Nauck, Michael; E. Nissen, Steven; Sattar, Naveed; Zinman, Bernard; Zoungas, Sophia; Basile, Jan; Bartee, Amy; L. Miller, Debra; Nishiyama, Hiroshi; Pávó, Imre; J. Weerakkody, Govinda; J. Wiese, Russell; A. D’Alessio, David

doi:10.1016/j.ahj.2023.09.007

Public

Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics

Published in American Heart Journal • Sep 25, 2023

Authors:

Stephen J. Nicholls

Deepak L. Bhatt

John B. Buse

Abstract

Tirzepatide, a once weekly GIP/GLP-1 receptor agonist, reduces blood glucose and body weight in people with type 2 diabetes. The cardiovascular (CV) safety and efficacy of tirzepatide have not been definitively assessed in a cardiovascular outcomes trial. Tirzepatide is being studied in a randomized...

Subject

Medicine

Type 2 diabetes

Disease

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!